Summary Rice bran is a rich source of functional compounds, including tocotrienol (T3) and ferulic acid (FA). We previously investigated the anti-cancer properties of T3, and reported on the potent inhibitory effects of d-T3 on angiogenesis and telomerase activity. In this study, we examined the synergistic suppressive effects of the combination of d-T3 and FA on telomerase activity in DLD-1 human colorectal adenocarcinoma cells. Co-treatment with d-T3 and FA significantly decreased cellular telomerase activity compared to treatment with d-T3 alone, whereas FA alone had no inhibitory effect. Co-treatment with d-T3 and FA also synergistically down-regulated the expression of human telomerase reverse transcriptase (hTERT), the catalytic subunit of telomerase, indicating that the enzymatic activity of telomerase is controlled at the transcriptional level. FA significantly increased the intracellular concentration of d-T3, suggesting that FA improved the bioavailability of d-T3, thereby increasing the inhibitory potency of d-T3 on telomerase. FA may be a promising candidate for augmenting the anti-cancer activity of d-T3.
Telomeres, the ends of eukaryotic chromosomes, are composed of guanine-rich sequences that are necessary for preserving chromosomal integrity and genome stability (1) . Since conventional DNA polymerases cannot completely copy the extreme ends of linear DNA, telomeres shorten by about 50-200 bases with each round of cell division in normal human somatic cells. When telomeres eventually reach a critical length, cell senescence occurs.
Human telomerase is a ribonucleoprotein enzyme complex that adds tandem arrays of the TTAGGG sequence to telomere ends. The enzyme essentially consists of human telomerase RNA component (hTR) and human telomerase reverse transcriptase (hTERT), both of which contribute to the maintenance of telomere length, thus enabling cells to overcome the Hayflick limit (2) . Telomerase activity is undetectable in normal cells, except for germ cells and stem cells, but is present in immortalized cell lines and in 80-90% of human cancer specimens (3) . Therefore, human telomerase is a potentially promising target for selective cancer treatment.
Vitamin E (Fig. 1A) is the generic name for a family of eight different compounds: a-, b-, g-, and d-isomers of both tocopherol (Toc) and tocotrienol (T3). The main difference between Toc and T3 is the degree of saturation of their side chain. Toc has a fully saturated phytyl side chain, whereas T3 contains an unsaturated isoprenoid tail with three double bonds (4) . The broad beneficial activities of T3, such as its anti-oxidative (5), anti-tumor (6), anti-hypercholesterolemic (7) , and neuroprotective (8) effects, have been gaining recent attention. Intriguingly, these bioactivities are generally superior to those of Toc. We previously investigated the anti-cancer properties of T3 and discovered that it inhibits both angiogenesis (9) and telomerase activity (10) . Specifically, T3 dose-dependently modulated cellular telomerase activity by repressing hTERT mRNA expression in DLD-1 human colorectal adenocarcinoma cells. This suggests that telomerase activity is controlled at the transcriptional level by T3. We also found that d-T3 exhibits the most potent anti-tumor activity of the four T3 isomers (10) .
More recently, we reported that a combination of rice bran components, particularly d-T3 and ferulic acid (FA; a potent phenolic antioxidant) (Fig. 1B) , synergistically inhibited the proliferation of an array of cancer cell lines, including PANC-1 (pancreatic cancer), MCF-7 (breast cancer), and DU-145 (prostate cancer) cells, through G1 cell cycle arrest (11) . FA increased the intercellular concentration of d-T3 (11), suggesting that FA can modulate the bioavailability of d-T3, thereby enhancing the inhibitory potency of d-T3 on cancer cell proliferation. Against this backdrop, we hypothesized E-mail: eitsuka@nupals.ac.jp that co-treatment with d-T3 and FA would not only inhibit cancer cell proliferation, but would also enhance the various physiological activities of d-T3. To this end, this study aimed to determine whether co-treatment of DLD-1 cells with d-T3 and FA synergistically down-regulates telomerase activity.
MATERIALS AND METHODS

Materials. d-T3
and FA were obtained from Eisai Co., Ltd. (Tokyo, Japan) and Wako Pure Chemical Industries, Ltd. (Osaka, Japan), respectively. RPMI 1640 medium (containing 0.3 mg/mL l-glutamine and 2.0 mg/mL sodium bicarbonate) was purchased from Sigma (St. Louis, MO). Fetal bovine serum (FBS) was from Funakoshi Co., Ltd. (Tokyo, Japan). Penicillin and streptomycin were from Gibco (Rockville, MD). The primary antibodies for hTERT and GAPDH were obtained from Epitomics (Burlingame, CA) and Cell Signaling Technologies (Danvers, MA), respectively.
Cell culture. DLD-1 human colorectal adenocarcinoma cells provided by the Cell Resource Center for Biomedical Research at Tohoku University School of Medicine (Sendai, Japan) were cultured in growth medium (RPMI-1640 medium supplemented with 10% FBS, 100 units/mL penicillin, and 100 mg/mL streptomycin) at 37˚C in a humidified atmosphere of 95% air and 5% CO2.
MTT assay. Test medium was prepared from growth medium supplemented with d-T3 and/or FA (dissolved in ethanol at various concentrations). The final concentration of ethanol in the test medium was 0.1% (v/v). DLD-1 cells were seeded onto a 96-well plate at a density of 5.0310 3 cells/well in 100 mL of growth medium. After incubation for 24 h, the medium was removed, and cells were cultured in 100 mL of test medium. Cell proliferation was assessed with the MTT assay (12) .
Analysis of d-T3. Cellular incorporation and medium concentration of d-T3 were analyzed using high performance liquid chromatography (HPLC) with fluorescence detection using 2,2,5,7,8-pentamethyl-6-hydroxychroman as an internal standard as previously described (11, 13) . The HPLC system consisted of a LC-10AT VP pump (Shimadzu, Kyoto, Japan), a CTO-10AS VP column oven (Shimadzu) and C-R8A integrator (Shimadzu). Inertsil SIL 100A (4.63250 mm, 5 mm; GL Science, Tokyo, Japan) was used as the HPLC column. The mixture of hexane/1,4-dioxane/2-propanol (1,000 : 40:5, v/v/v) was used as the mobile phase. d-T3 was detected by a RF-10A XL detector (excitation 294 nm, emission 326 nm; Shimadzu). Cellular protein content was measured using the Bio-Rad protein assay (Bio-Rad, Hercules, CA), which is based on the Bradford dye-binding method (14) .
Detection of telomerase activity. Telomerase activity of DLD-1 cells was assessed by the stretch PCR assay (15) using a TeloChaser Kit (Toyobo, Osaka, Japan), which includes a 65-base pair (bp) internal control to quantify telomerase activity. Briefly, DLD-1 cells treated with test medium were suspended in lysis buffer (Toyobo), and the cell lysate (equivalent to 1.5310 4 cells) was subjected to the stretch PCR assay as recommended by the manufacturer. PCR products were electrophoresed on a 10% non-denaturing polyacrylamide gel and visualized with GelRed (Biotium, Hayward, CA). Relative telomerase activity was determined by measuring the band intensities of all six-base ladders and comparing them with those of the internal standard. Band intensity was measured using ImageJ 1.48v (National Institutes of Health, Bethesda, MD).
RNA isolation and quantitative real-time PCR. Total RNA was extracted with the NucleoSpin RNA II kit (Macherey-Nagel GmbH & Co. KG, Düren, Germany). cDNA was synthesized using the PrimeScript RT reagent kit (Takara, Ohtsu, Japan), followed by PCR amplification using SYBR Premix Ex Taq II (Takara) and gene specific primers for hTERT (Takara), GAPDH (Takara) and CYP4F2 (16) . Sequences of primer sets were as follows: hTERT (GenBank Acc: NM_198255NM), 5′-TGTGCTA-CGGCGACATGGA-3′ and 5′-GAGGTGAGGTGTCACCAA-CAAGAA-3′; GAPDH (GenBank Acc: NM_008084.3), 5′-TGTGTCCGTCGTGGATCTGA-3′ and 5′-TTGCTGTTG-AAGTCGCAGGAG-3′. Quantitative PCR was performed with the Thermal Cycler Dice Real Time System (Takara). Thermal cycling conditions comprised an initial denaturation step at 95˚C for 10 s and 40 cycles of 95˚C for 5 s and 60˚C for 30 s.
Western blot analysis. Total protein was extracted from DLD-1 cells using IP buffer, and the protein content was measured by the Bio-Rad protein assay. Equal amounts of protein (20 mg/lane) were separated by 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and separated proteins were transferred onto a polyvinylidene difluoride membrane (Millipore, Billerica, MA). After blocking with PVDF blocking reagent (Toyobo), the membrane was incubated with primary antibodies for hTERT (1 : 2,000) and GAPDH (1 : 2,000), followed by secondary antibodies (anti-rabbit IgG) conjugated with horseradish peroxidase (1 : 10,000, Cell Signaling Technologies). Target proteins were visualized by the addition of Immobilon Western Chemiluminescent HRP Substrate (Millipore), and images were obtained from the ChemiDoc MP system (Bio-Rad).
Statistical analysis. Data are presented as mean6SD of three independent experiments. Data were evaluated by one-way analysis of variance (ANOVA) followed by individual comparisons with the control using Dunnett's test. Statistical analysis among several groups was performed using ANOVA, followed by the Tukey-Kramer test for multiple comparisons. p,0.05 was considered significant.
RESULTS
Co-treatment with d-T3 and FA synergistically inhibits DLD-1 proliferation
To examine whether co-treatment of d-T3 with FA has a synergistic effect on DLD-1 cells, the growth inhibitory effects of d-T3 and FA were evaluated by MTT assay. In our previous in vitro study (11) , d-T3 inhibited the proliferation of cancer cell lines with significant inhibition observed at concentrations of $10 mm; d-T3 at 15-20 mm for 72 h exhibited potent cytotoxicity (11) . Therefore, d-T3 at a concentration range of 10-12.5 mm was chosen for examining synergy with FA. Treatment with 10-12.5 mm d-T3 for 72 h resulted in a dose-dependent inhibition of DLD-1 cell proliferation (Fig. 2) . On the other hand, FA treatment did not inhibit proliferation, even at a concentration of 50 mm (Fig. 2) . Co-treatment with 10-12.5 mm d-T3 and 10-50 mm FA significantly decreased cell proliferation compared with d-T3 alone; 50 mm FA alone had no inhibitory effect. These results indicate that the combination of d-T3 and FA synergistically inhibits the proliferation (Fig. 3A) . FA treatment had no effect on the amount of d-T3 in culture medium (Fig. 3B) . These results suggest that FA improves the bioavailability of d-T3, and that cellular d-T3 content controls the degree of d-T3-mediated inhibition of cell proliferation (Fig. 2) .
Synergistic inhibitory effect of d-T3 and FA on telomerase activity in DLD-1 cells
To investigate whether co-treatment with d-T3 and FA can modulate cellular telomerase activity as well as cell proliferation (Fig. 2) , the stretch PCR assay was performed to evaluate telomerase activity. In this assay, telomerase activity was determined based on the six-bp incremental DNA ladder of the telomerase product (see DNA ladder in the control lane in Fig. 4A ). Treatment of DLD-1 cells with 12.5 mm d-T3 for 72 h reduced the intensity of the six-base ladder (Fig. 4A) , indicating that d-T3 attenuates cellular telomerase activity. Cotreatment with d-T3 and FA had a stronger telomeraseinhibitory effect relative to d-T3 alone, even though 20 mm FA did not influence telomerase activity (Fig. 4B) . These results suggest that the combination of d-T3 and FA synergistically suppresses telomerase activity. 
Co-treatment with d-T3 and FA synergistically attenuates hTERT expression
hTERT is the catalytic subunit of telomerase, and its expression is a critical determinant of telomerase activity (17) . We next assessed the effects of d-T3 and FA on hTERT mRNA and protein expression in DLD-1 cells by real-time PCR and Western blot analysis, respectively. While treatment with 20 mm FA alone had no effect on either hTERT mRNA (Fig. 5A) or protein (Fig. 5B ) levels, 12.5 mm d-T3 markedly down-regulated both hTERT mRNA and protein levels ( Fig. 5A and B) . Co-treatment with d-T3 and FA efficiently decreased hTERT mRNA and protein levels as compared to d-T3 alone (Fig. 5A  and B) . These data suggest that the combination of d-T3 and FA synergistically inhibits cellular telomerase activity by reducing hTERT expression.
DISCUSSION
T3 has been shown to decrease the proliferation of cancer cells derived from breast, colon, liver, lung, stomach, skin, pancreas, prostate, blood, and cervix (6) . The growth suppressive effects of T3 are attributed to apoptosis and G1 cell cycle arrest. Several efforts are ongoing to screen for agents that can potentially synergize with T3 in order to enhance its efficacy. Combinations of T3 and chemotherapeutic agents, including statins (18), celecoxib (19) , erlotinib/gefitinib (20) , GW966/T0070907 (21), epigallocatechin gallate/resveratrol (22) , and sesamin (23), have synergistic effects on tumor growth and signaling pathways. Of these agents, sesamin elevates the intracellular concentration of T3 by inhibiting cytochrome P450 4F2 (CYP4F2), an enzyme that mediates vitamin E metabolism (24). Akl et al. (23) reported that T3 and sesamin synergistically decreased1SA mouse mammary epithelial cell proliferation. As shown in Figs. 2 and 3, co-treatment of DLD-1 cells with d-T3 and FA synergistically inhibited proliferation by increasing cellular concentrations of d-T3. These findings suggest that sesamin and FA may synergize with T3 through a similar mode of action (i.e., increasing the concentration of T3). In fact, we confirmed the expression of CYP4F2 mRNA in DLD-1 cells using real-time PCR (data not shown).
The treatment with d-T3 and FA for 72 h resulted in significant synergistic inhibition of DLD-1 cell growth (Fig. 2) , telomerase activity (Fig. 4) and hTERT expression (Fig. 5) . As seen in Fig. 3 , co-administration of d-T3 and FA for 48 h or more augmented cellular concentration of d-T3 (Fig. 3) . These synergistic effects (Figs. 2, 4 and 5) were observed after elevation of intracellular d-T3 content (Fig. 3) . Thus, these results imply that the synergies are mainly due to an increase in the cellular concentration of d-T3 by FA. On the other hand, FA did not affect the amount of d-T3 in culture medium (Fig.  3B) , suggesting that FA is unlikely to influence the cellular incorporation of d-T3.
We reported that a combination of d-T3 and FA synergistically inhibited the proliferation of PANC-1, MCF-7 and DU-145, and revealed that the sensitivity to the combination was different among the cell types; the ranked order of the sensitivity was PANC-1.MCF-7. DU-145 (11) . As seen in Fig. 2 , DLD-1 as well as DU-145 might have a low sensitivity to the synergistic growthinhibitory effect of d-T3 and FA.
FA is a ubiquitous component of cell walls in plants, such as rice, wheat, and barley. Owing to its phenolic nucleus and unsaturated side chain (Fig. 1B) , FA can easily form a resonance-stabilized phenoxy radical, thereby accounting for its potent antioxidant activity. FA has received much attention recently, given its wide range of beneficial effects against cancer (25) , cardiovascular disease (26) , diabetes (27) , and Alzheimer's disease (28) . Most of its health-promoting properties are thought to be attributable to its anti-oxidative effects. The beneficial bioactivity of FA is derived from its absorption and pharmacokinetic properties. Previous studies have shown that FA is more bioavailable than dietary flavonoids and is retained in blood for a longer duration than other antioxidants such as ascorbic acid (29) . Zhao et al. (30) investigated its bioavailability using rats. In that study, rats administered 70 mmol/kg body of FA had a plasma concentration of FA of 25.3610.1 mm at 5 min after administration. These observations indicate that physiological concentrations of FA can potentiate the inhibitory effects of d-T3 on DLD-1 cell proliferation (Fig. 2 ) and telomerase activity (Fig. 4) , and suggest that FA may be a promising candidate for augmenting the anti-cancer activity of d-T3.
The presence of telomerase in 80-90% of human cancer cells indicates that the enzyme might serve as a promising target for cancer therapy. Telomerase inhibitors are likely to contribute to killing tumor cells by inducing senescence or apoptosis through telomere shortening. Therefore, many different classes of anticancer compounds directed against telomerase have been screened and developed (31) . In our recent studies, we found that certain food lipids, including sulfoquinovosyldiacylglycerol (32), polyunsaturated fatty acids (particularly eicosapentaenoic acid and docosahexaenoic acid) (33) , and T3 (particularly b-and d-isomers) (10), can act as potent telomerase inhibitors.
We confirmed that d-T3 and FA synergistically inhibited telomerase activity in PANC-1 and MCF-7 cells (data not shown). The result indicates that this combination treatment might apply to not only colorectal but also pancreatic and breast cancer cells. Moreover, a combination of b-T3 and FA synergistically reduced cellular telomerase activity in DLD-1 (data not shown), suggesting that the synergy effect is not specific to d-T3 but applicable to other T3 isomers.
hTERT mRNA levels and telomerase activity are positively correlated in extracts from cultured cells and tissues. On the other hand, hTR is expressed constitutively in both cancer and normal cells, independently of the status of telomerase expression (17) . These findings strongly suggest that hTERT is the rate-limiting determinant of telomerase activity. As shown in Fig. 5 , we found that d-T3 markedly reduced hTERT mRNA expression, thereby inhibiting telomerase activity. Thus, d-T3 can modulate telomerase at the transcriptional level.
The hTERT promoter is a key regulatory element for telomerase expression, and includes an array of binding sites for various transcription factors (34) . The transcription factor c-myc acts as a pivotal regulator of hTERT transcription by binding to an E-box (CACGTG) in the promoter (34) . The expression of c-myc highly correlates with the expression of hTERT (35) . In a previous study, we found that T3 reduced hTERT expression by down-regulating c-myc, thereby reducing cellular telomerase activity (10) . Thus, the reduction in hTERT expression we observed (Fig. 5) could involve the repression of c-myc by d-T3. Since oncogene c-myc is involved in the control of cell growth (36) , it is conceivable that c-myc inhibition elicits not only down-regulation of hTERT (Fig. 5) but also suppression of cell growth (Fig.  2) .
In conclusion, we demonstrated that co-treatment with d-T3 and FA synergistically inhibits cellular telomerase activity by suppressing hTERT expression in DLD-1 cells. This synergistic effect was related to the FAmediated increase in intracellular d-T3 concentration. Further experiments, especially in vivo studies, will be needed to evaluate the usefulness of combination treatment with d-T3 and FA.
